Subject to regulatory approval, the Swiss stock exchange will launch its new Sparks equity segment dedicated to Small & Medium Enterprises (SMEs). These companies will benefit from enhanced visibility, a more relevant peer group and more effective price formation in their equity securities while benefiting from all the well-known advantages of being a listed company on the Swiss stock exchange.
Interest from SMEs in the unique benefits of public capital markets has been on the rise for a number of years. Venture-capital investments alone have increased five-fold in Switzerland over the past decade (see illustration from startupticker.ch), enabling more entrepreneurs to test and develop their product and service ideas with a view to growing their businesses. The broader impact of such investment growth has been a rise in the number of SMEs that have matured to the point of taking the next step in their development to go public.
Sparks, a dedicated new equity segment on the Swiss stock exchange, will provide a key piece in addressing this need of SMEs and their investors for a dedicated, tailored, regulated exchange venue. In establishing and growing a well-functioning ecosystem for raising public capital the continual and concerted efforts of the broader Swiss financial centre will also be very important.
According to Valeria Ceccarelli, Head Primary Markets, SIX Swiss Exchange, “SMEs in Switzerland – as in many countries – are a powerful economic engine. Our challenge has been to ensure that we can offer entrepreneurs a platform that can help them efficiently access capital, enhance their visibility, strengthen their credibility, and provide the levels of transparency and scrutiny that maximize investor interest. With Sparks, we will be able to achieve the right balance of all of these elements as well as to contribute meaningfully to the growth of SMEs and, more broadly, to that of the Swiss economy.”
SIX is committed to ensuring that the backbone of the Swiss economy — fast-growing and established SMEs — can benefit from the unique advantages of public capital markets. Sparks will be the next step in SIX’s ongoing efforts to enhance its offering to this segment. It follows services such as Stage, which unlocks independent research coverage for SMEs, conferences connecting SMEs with investors, education workshops, and e-learning solutions.
Further information on Sparks.
Priority medicines (PRIME) is a scheme run by the European Medicines Agency (EMA) to enhance support for the development of medicines that target an unmet medical need. The scheme is based on enhanced interaction and early dialogue with developers of promising medicines, to optimize development plans and speed up evaluation so these medicines can reach patients earlier EMA CHMP acknowledges that n
LubioScience GmbH, Switzerland’s leading Life Sciences platform, expands its product portfolio with the addition of fresh human blood products and biospecimens provided by Research Donors from the UK.
Preliminary data from 472 nine-month-old infants confirm favorable safety and tolerability profile and demonstrate significant immunogenicity for the four most common pathogen serotypes Results support further development with LimmaTech expecting to initiate the next clinical trial in 2024 Topline results from the completed Phase I/II will be reported in the first half of 2024
InterAx Biotech AG, a product development company pioneering computational pharmacology for drug discovery, announces that the company's most advanced artificial intelligence platform has uncovered novel cellular signaling modes of action which enable InterAx to design efficacious orally available drugs for diabetes, obesity, and immuno oncology. Particularly promising results are coming from the
Its proprietary innovative polymer technology reduces bacterial bioburden without triggering antimicrobial resistance, one of the top global public health threats The Advanced Wound Dressing (AWD) market is valued at 4.5 billion USD and is witnessing increasing demand and technological advancements The company is looking to expand development and commercial collaborations with industry leaders
Vandria is advancing a portfolio of mitophagy inducers to address age-related chronic diseases of the CNS, muscle, lung and liver Innosuisse grant totalling CHF 2.5M (€ 2.7M) to support early clinical development plan for lead CNS mitophagy drug candidate VNA-318 that has the potential to treat cognitive impairment, dementia, Alzheimer’s and Parkinson’s Disease Eurostars grant totalling €1